Editorials Newly licensed drugs BMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7066.1157 (Published 09 November 1996) Cite this as: BMJ 1996;313:1157 Article Related content Metrics Responses Peer review Related articles Editorial The influence of big pharma Published: 14 April 2005; BMJ 330 doi:10.1136/bmj.330.7496.855 Analysis And Comment How NICE may be outflanked Published: 25 May 2006; BMJ 332 doi:10.1136/bmj.332.7552.1268 See more Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis BMJ December 05, 2016, 355 i6188; DOI: https://doi.org/10.1136/bmj.i6188 NHS to fund large trial of pre-exposure prophylaxis for HIV prevention BMJ December 05, 2016, 355 i6537; DOI: https://doi.org/10.1136/bmj.i6537 Bill to boost medical research funding and speed drug approval passes US house BMJ December 01, 2016, 355 i6498; DOI: https://doi.org/10.1136/bmj.i6498 Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis BMJ December 01, 2016, 355 i6112; DOI: https://doi.org/10.1136/bmj.i6112 Sixty seconds on . . . solanezumab BMJ November 29, 2016, 355 i6389; DOI: https://doi.org/10.1136/bmj.i6389 Cited by... How NICE may be outflankedFulltext PDF The influence of big pharmaFulltext PDF Failures of the therapeutic chain as a cause of drug ineffectivenessFulltext PDF Prescribing new drugs: qualitative study of influences on consultants and general practitionersFulltext PDF Abstract Too soon to marketFulltext PDF Abstract Too soon to marketFulltext PDF Abstract How to read a paper: Papers that report drug trialsFulltext PDF Abstract Newly licensed drugsFulltext PDF Abstract Interferon beta in multiple sclerosisFulltext PDF Abstract New antiepileptic drugsFulltext PDF Abstract